NovaSecta's business is centered on providing smaller to mid-sized pharmaceutical and biotech companies the scale advantages that Big Pharmas enjoy while allowing them to remain independent, fast and flexible.  This alliance is therefore a natural step in NovaSecta's evolution as an R&D services company. "We selected Sundia Meditech and HD BioSciences as our alliance partners based on their professionalism and track record in repeatedly delivering drug discovery solutions to their US and multi-national clients.  Combining the skills and demonstrated drug discovery track record of their scientific teams with the expertise of European drug discovery scientists will surely lead to faster and more efficient generation of high quality drug candidates" said Robert Thong and John Rountree, NovaSecta's co-founders and Managing Directors.

HD BioSciences, Sundia Meditech, and United PharmaTech entered into a CRO Service Alliance in May 2007.   The initial alliance was formed to quickly and successfully expand into the complete range of CRO services to fit the increased demands from clients worldwide while maintaining high quality and efficiency and minimizing cost.  "We believe that by extending our alliance to include NovaSecta, we will bring significant benefits to European customers, so we look forward to working with NovaSecta and more European clients," said Dr. Xiaochuan Wang, Sundia Meditech's founder and CEO and Dr. Xuehai Tan, HD BioSciences' founder and CEO.